Cerenome Reports Q2 2026 Net Loss of $9.0M, Cash at $8.6M
CNSY sits 21% above its 52-week low of $2.9.
Summary
Cerenome reported a Q2 2026 net loss of $9.0 million on $0.4 million in grant revenue, with cash and investments of $8.6 million. The company affirmed its 2026 milestones but faces a significant cash burn as it scales CNSide and advances REYOBIQ.
Key Events · Earnings and Guidance · CNSY
-
Q2 Net Loss Widens to $9.0M
Net loss of $9.0 million ($1.31/share) in Q2 2026 versus net income of $5.2 million ($0.62/share) in Q2 2025, which included a $6.5 million non-cash derivative fair-value gain.
-
Cash Position at $8.6M
Cash, cash equivalents and investments totaled $8.6 million as of June 30, 2026, down from $8.6 million at December 31, 2025, with operating cash burn of $13.4 million in H1 2026.
-
CNSide Commercial Progress
Performed 232 CNSide CSF tests in H1 2026 and achieved 150 million covered lives for commercial payer coverage, meeting the 2026 corporate objective by mid-year.
-
REYOBIQ Clinical Milestones
ReSPECT-LM trial approximately one-third enrolled with no dose-limiting toxicities; ReSPECT-GBM full enrollment expected in 2026 with data readout in Q1 2027; ReSPECT-PBC first dosing expected in Q3 2026.
Analysis · CNSY · Industrial Applications And Services
Cerenome's second quarter results show a sharp widening of losses as the company invests heavily in its CNSide commercial rollout and REYOBIQ clinical trials. The net loss of $9.0 million compares to net income of $5.2 million a year ago, which had benefited from a one-time $6.5 million derivative fair-value gain. Cash and investments of $8.6 million provide limited runway given the current burn rate, making future capital raises likely. The company affirmed its 2026 milestones, including full enrollment in the ReSPECT-GBM trial and expansion of CNSide payer coverage, but the financials underscore the cash consumption required to reach those goals.
At the time of this filing, CNSY was trading at $3.50 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $25.3M. The 52-week trading range was $2.90 to $23.43. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.